BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 22261812)

  • 21. [Secondary mutation of c-kit/PDGFRα genotypes after imatinib mesylate therapy and its relationship with efficacy of sunitinib].
    Hong JL; Li J; Li J; Shen L
    Zhonghua Bing Li Xue Za Zhi; 2012 Jun; 41(6):386-90. PubMed ID: 22932406
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
    Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
    Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
    Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
    Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GAB2 amplifications refine molecular classification of melanoma.
    Chernoff KA; Bordone L; Horst B; Simon K; Twadell W; Lee K; Cohen JA; Wang S; Silvers DN; Brunner G; Celebi JT
    Clin Cancer Res; 2009 Jul; 15(13):4288-91. PubMed ID: 19509136
    [TBL] [Abstract][Full Text] [Related]  

  • 25. c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis.
    Steeb T; Wessely A; Petzold A; Kohl C; Erdmann M; Berking C; Heppt MV
    Eur J Cancer; 2021 Nov; 157():348-357. PubMed ID: 34562816
    [TBL] [Abstract][Full Text] [Related]  

  • 26. c-kit gene mutation and CD117 expression in human anorectal melanomas.
    Ni S; Huang D; Chen X; Huang J; Kong Y; Xu Y; Du X; Sheng W
    Hum Pathol; 2012 Jun; 43(6):801-7. PubMed ID: 22154054
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature.
    Satzger I; Küttler U; Völker B; Schenck F; Kapp A; Gutzmer R
    Dermatology; 2010; 220(1):77-81. PubMed ID: 19996579
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.
    Willmore-Payne C; Holden JA; Tripp S; Layfield LJ
    Hum Pathol; 2005 May; 36(5):486-93. PubMed ID: 15948115
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607).
    Kalinsky K; Lee S; Rubin KM; Lawrence DP; Iafrarte AJ; Borger DR; Margolin KA; Leitao MM; Tarhini AA; Koon HB; Pecora AL; Jaslowski AJ; Cohen GI; Kuzel TM; Lao CD; Kirkwood JM
    Cancer; 2017 Jul; 123(14):2688-2697. PubMed ID: 28334439
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.
    Guo J; Si L; Kong Y; Flaherty KT; Xu X; Zhu Y; Corless CL; Li L; Li H; Sheng X; Cui C; Chi Z; Li S; Han M; Mao L; Lin X; Du N; Zhang X; Li J; Wang B; Qin S
    J Clin Oncol; 2011 Jul; 29(21):2904-9. PubMed ID: 21690468
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma: a case report.
    Rapisuwon S; Parks K; Al-Refaie W; Atkins MB
    Melanoma Res; 2014 Oct; 24(5):509-11. PubMed ID: 25003536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure.
    Handolias D; Salemi R; Murray W; Tan A; Liu W; Viros A; Dobrovic A; Kelly J; McArthur GA
    Pigment Cell Melanoma Res; 2010 Apr; 23(2):210-5. PubMed ID: 20088873
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The potential role of sunitinib targeting melanomas.
    Valsecchi ME; Sato T
    Expert Opin Investig Drugs; 2013 Nov; 22(11):1473-83. PubMed ID: 24050392
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in targeted therapy for melanoma.
    Friedlander P; Hodi FS
    Clin Adv Hematol Oncol; 2010 Sep; 8(9):619-27. PubMed ID: 21157411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of KIT expression and gene mutation in human acral melanoma: with a comparison between primary tumors and corresponding metastases/recurrences.
    Dai B; Cai X; Kong YY; Yang F; Shen XX; Wang LW; Kong JC
    Hum Pathol; 2013 Aug; 44(8):1472-8. PubMed ID: 23528861
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor.
    Prior JO; Montemurro M; Orcurto MV; Michielin O; Luthi F; Benhattar J; Guillou L; Elsig V; Stupp R; Delaloye AB; Leyvraz S
    J Clin Oncol; 2009 Jan; 27(3):439-45. PubMed ID: 19064982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Large-scale analysis of KIT aberrations in Chinese patients with melanoma.
    Kong Y; Si L; Zhu Y; Xu X; Corless CL; Flaherty KT; Li L; Li H; Sheng X; Cui C; Chi Z; Li S; Han M; Mao L; Lu A; Guo J
    Clin Cancer Res; 2011 Apr; 17(7):1684-91. PubMed ID: 21325067
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases.
    Sperduto PW; Jiang W; Brown PD; Braunstein S; Sneed P; Wattson DA; Shih HA; Bangdiwala A; Shanley R; Lockney NA; Beal K; Lou E; Amatruda T; Sperduto WA; Kirkpatrick JP; Yeh N; Gaspar LE; Molitoris JK; Masucci L; Roberge D; Yu J; Chiang V; Mehta M
    Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1069-1077. PubMed ID: 28721890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nilotinib in patients with metastatic melanoma harboring KIT gene aberration.
    Cho JH; Kim KM; Kwon M; Kim JH; Lee J
    Invest New Drugs; 2012 Oct; 30(5):2008-14. PubMed ID: 22068222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. KIT amplification and gene mutations in acral/mucosal melanoma in Korea.
    Yun J; Lee J; Jang J; Lee EJ; Jang KT; Kim JH; Kim KM
    APMIS; 2011 Jun; 119(6):330-5. PubMed ID: 21569090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.